Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on ...

Regeneron Pharmaceuticals (REGN) has grabbed investor attention this week, as recent positive late-stage clinical data and a ...

FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

Regeneron Pharmaceuticals' Libtayo won approval to treat certain patients with cutaneous squamous cell carcinoma, a type of skin cancer, from the Food and Drug Administration. The pharmaceutical ...

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

US biotech Regeneron Pharmaceuticals revealed that the US Food and Drug Administration (FDA) has approved the PD-1 inhibitor ...